Controllable Synthesis of Self-Assembled Nitroimidazole-Based Nanocomplexes for Enhanced Chemodynamic Therapy by Dual-Channel Modulation of Glutathione
Source abstract
Abstract
Chemodynamic therapy (CDT) offers an effective in situ activation therapy for cancer treatments. However, the efficiency of CDT is limited by the antioxidant system within tumor cells, including antioxidative niacinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH). Zeolitic imidazolate framework-8 (ZIF-8) is widely used in tumor therapies due to its tunable structure and properties, but ZIF-8 itself lacks CDT application. In order to meet the application demand of CDT, we select Cu 2+ ions that can catalyze a Fenton-like reaction and 2-nitroimidazole (2-NI) that can consume NADPH as new inorganic–organic connection components. Based on the reasonable coordination mode of ZIF-8, a CDT nanoplatform with an adjustable size is constructed. The synthesized Cu-NI NPs are triple responsive to hypoxia, GSH, and hydrogen peroxide (H 2 O 2 ), which selectively enhance Cu + /Cu 2+ -mediated CDT and induce tumor apoptosis/ferroptosis. This work will promote the diversification of ZIF-8 structures and properties, and provide good implications for the realization of enhanced CDT.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Metal-Organic Frameworks: Synthesis and Applications · Sulfur Compounds in Biology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China
Funding
Jilin Provincial Scientific and Technological Development Program · National Natural Science Foundation of China
References (35)
Show source-provided references
1. 10.1002/anie.20221041510.1002/anie.202210415 ↗
2. 10.1021/acsami.2c1109110.1021/acsami.2c11091 ↗
3. 10.1002/EXP.2021023810.1002/EXP.20210238 ↗
4. 10.1002/EXP.2023012710.1002/EXP.20230127 ↗
5. 10.1016/j.jconrel.2021.02.03010.1016/j.jconrel.2021.02.030 ↗
6. 10.1002/smll.20220782510.1002/smll.202207825 ↗
7. 10.1016/j.redox.2020.10168510.1016/j.redox.2020.101685 ↗
8. 10.3389/fendo.2018.0009310.3389/fendo.2018.00093 ↗
9. 10.1002/anie.20230123210.1002/anie.202301232 ↗
10. 10.1016/j.nantod.2022.10157410.1016/j.nantod.2022.101574 ↗
11. 10.1016/j.actbio.2022.12.06710.1016/j.actbio.2022.12.067 ↗
12. 10.1002/anie.20210625910.1002/anie.202106259 ↗
13. 10.1021/accountsmr.3c0009710.1021/accountsmr.3c00097 ↗
14. 10.1002/anie.20221530710.1002/anie.202215307 ↗
15. 10.1021/acsnano.2c0358710.1021/acsnano.2c03587 ↗
16. 10.1002/anie.20231402510.1002/anie.202314025 ↗
17. 10.1021/jacs.1c1185610.1021/jacs.1c11856 ↗
18. 10.1016/j.jconrel.2023.07.05010.1016/j.jconrel.2023.07.050 ↗
19. 10.1016/j.ijbiomac.2021.12.15010.1016/j.ijbiomac.2021.12.150 ↗
20. 10.1002/anie.20200511110.1002/anie.202005111 ↗
21. 10.1002/advs.20200154910.1002/advs.202001549 ↗
22. 10.1021/acsnano.0c0076410.1021/acsnano.0c00764 ↗
23. 10.1021/acs.chemrev.6b0052510.1021/acs.chemrev.6b00525 ↗
24. 10.1038/s41392-020-00326-010.1038/s41392-020-00326-0 ↗
25. 10.1038/s41589-023-01298-210.1038/s41589-023-01298-2 ↗
26. 10.1002/INMD.2023000210.1002/INMD.20230002 ↗
27. 10.1002/advs.20220378810.1002/advs.202203788 ↗
28. 10.1016/j.apsb.2022.05.02710.1016/j.apsb.2022.05.027 ↗
29. 10.1038/s41587-023-01957-810.1038/s41587-023-01957-8 ↗
30. 10.1016/j.jcis.2023.03.05710.1016/j.jcis.2023.03.057 ↗
31. 10.1002/anie.20210301510.1002/anie.202103015 ↗
32. 10.1002/INMD.2022000510.1002/INMD.20220005 ↗
33. 10.1039/c3dt51322j10.1039/c3dt51322j ↗
34. 10.1021/acsami.7b0288710.1021/acsami.7b02887 ↗
35. 10.1021/jacs.3c0448010.1021/jacs.3c04480 ↗